top of page
its lead candidate, vs-01, has the potential to be the first treatment for acute-on-chronic liver failure, simultaneously supporting multiple failing organs. in 2022 genfit acquired versantis.
acquired by genfit
versantis is a clinical-stage biotech company developing novel drug therapies to treat liver, pediatric, and rare diseases, addressing currently unmet medical needs. based on its proprietary detoxification platform technology, versantis is pursuing innovative therapies for the critical care of serious liver conditions, such as acute-on-chronic liver failure or urea cycle disorder (ucd).
novel drug therapies to address unmet medical needs
rac III
healthtech
2017
2015
fund
sector
invested in
founded
bottom of page